Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
#Pharmaceuticals Native Starch Market Forecast: What Value Will The Market Reach By 2030?#_x000D_
The pharmaceuticals native starch market size has shown significant growth in recent years. This market is expected to expand from $6.11 billion in 2025 to $6.64 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. The historical growth of this market stemmed from factors including the accessibility of natural starch sources, the rise of generic pharmaceuticals, the widespread application in tablets and capsules, cost sensitivity in drug manufacturing, and the regulatory acceptance of native starch._x000D_
_x000D_
The pharmaceuticals native starch market is predicted to experience significant expansion over the next few years. It is expected to grow to $9.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. This growth during the forecast period is driven by an increase in clean-label drug formulations, stricter sustainability requirements, the expansion of pharmaceutical manufacturing into emerging markets, a rising demand for biodegradable excipients, and advancements in starch processing. Major trends anticipated during this period include a growing demand for natural and clean-label excipients, increasing utilization in solid oral dosage forms, greater adoption as a binder and disintegrant, the expansion of plant-based pharmaceutical ingredients, and an increasing focus on cost-effective excipients._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Pharmaceuticals Native Starch Market Growth Factors Behind Sustained Expansion#_x000D_
The increasing prevalence of chronic diseases is anticipated to propel the growth of the pharmaceuticals native starch market moving forward. Chronic conditions are long-term medical issues that typically progress slowly and last for a year or more. The rising incidence of chronic diseases is primarily attributed to an aging population, as older individuals are more susceptible to long-term health problems such as diabetes, cardiovascular diseases, arthritis, and cancer, which become more common with advancing age. Pharmaceuticals native starch is beneficial for chronic diseases by enhancing drug formulation stability, improving bioavailability, enabling controlled drug release, supporting patient adherence, and ultimately strengthening the effectiveness and long-term management of chronic medical conditions. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal public health agency, 76.4% of U.S. adults, representing approximately 194 million people, reported having one or more chronic conditions in 2023, with prevalence at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the growing prevalence of chronic diseases is driving the expansion of the pharmaceuticals native starch market. The expansion of generic drug manufacturing is expected to propel the growth of the pharmaceuticals native starch market in the future. Generic drug manufacturing refers to the production of off-patent medications that are bioequivalent to branded drugs. Generic drug manufacturing is on the rise due to increasing regulatory support that accelerates approvals and encourages more companies to produce affordable alternatives to branded medicines. The growth of generic drug manufacturing supports pharmaceuticals native starch by increasing the need for reliable, cost-effective excipients that enhance tablet formulation, stability, and drug delivery efficiency across a broader range of high-volume generic medicines. For instance, in November 2024, according to the Food and Drug Administration (FDA), a US-based federal agency, in FY 2023, the FDA approved 782 Abbreviated New Drug Applications (ANDAs), an increase from 722 approvals recorded in FY 2022. Therefore, the expansion of generic drug manufacturing is driving the growth of the pharmaceuticals native starch market._x000D_
_x000D_
#Pharmaceuticals Native Starch Market Segments: Where Is Growth Concentrated?#_x000D_
The pharmaceuticals native starch market covered in this report is segmented – _x000D_
_x000D_
1) By Type: Potato Starch, Corn Starch, Other Types_x000D_
2) By Formulation Type: Oral Solid Dosage Forms, Liquid Dosage Forms, Topical Formulations, Injectable Drugs, Controlled Release Formulations_x000D_
3) By Functionality: Texturizing Agent, Moisture Retention Agent, Bulking Agent, Emulsifying Agent, Film-Forming Agent_x000D_
4) By Application: Binders And Coating Agents, Disintegrants, Fillers And Extenders, Stabilizers, Thickening Agents_x000D_
5) By End-User: Pharmaceutical Manufacturers, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Research And Development Labs, Academic Institutions, Other End-users_x000D_
_x000D_
Subsegments:_x000D_
1) By Potato Starch: Native Potato Starch (Pharmaceutical Grade), Low Moisture Native Potato Starch, Fine Particle Size Native Potato Starch, High Purity Native Potato Starch_x000D_
2) By Corn Starch: Native Corn Starch (Pharmaceutical Grade), Low Moisture Native Corn Starch, Fine Particle Size Native Corn Starch, High Purity Native Corn Starch_x000D_
3) By Other Types: Rice Starch, Wheat Starch, Tapioca Starch_x000D_
_x000D_
#Pharmaceuticals Native Starch Market Industry Trends Fueling Future Revenue Growth#_x000D_
Leading companies in the pharmaceuticals native starch market are focusing on developing innovative products, such as plant-based textures, to enhance drug formulation and improve patient compliance. Plant-based texture refers to the physical properties derived from plant ingredients, such as thickness and gel strength, and helps pharmaceuticals utilize native starch by improving tablet binding, disintegration, and mouthfeel for enhanced natural drug formulations. For instance, in February 2024, Ingredion Incorporated, a US-based food company, launched Novation Indulge 2940 starch, a clean-label texturizer aimed at improving texture and stability in dairy and alternative dairy products. This innovative pharmaceutical native starch offers functional properties that enhance drug formulation performance, bioavailability, and controlled release while supporting the development of clean-label, sustainable products. NOVATION Indulge 2940 starch is a versatile ingredient that improves texture, stability, and consumer acceptance in both dairy and alternative dairy products, using clean-label, natural ingredients._x000D_
_x000D_
#Pharmaceuticals Native Starch Market Key Participants And Competitive Landscape#_x000D_
Major companies operating in the pharmaceuticals native starch market are Cargill Incorporated, Archer Daniels Midland Company, Ingredion Incorporated, Roquette Frères SA, Emsland Group, Tereos SCA, AGRANA Beteiligungs-AG, Grain Processing Corporation, Universal Starch-Chem Allied Ltd., SPAC Starch Products (India) Private Limited, Sanstar Biopolymers Ltd., Gulshan Polyols Ltd., Tate & Lyle Public Limited Company, BENEO GmbH, Hungrana Kft., Bluecraft Agro Pvt. Ltd., Visco Starch, Manildra Group, Shandong Liujia Pharmaceutical Excipient Co. Ltd., Zhucheng Xingmao Corn Developing Co. Ltd. _x000D_
_x000D_
#View The Full Pharmaceuticals Native Starch Market Report:#_x000D_
_x000D_
#Pharmaceuticals Native Starch Market Global Footprint: Which Region Leads The Market?#_x000D_
North America was the largest region in the pharmaceuticals native starch market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceuticals native starch market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model